梅州女性附件炎的治疗方案梅州妇科慢性附件炎怎样治疗,梅州霉菌性阴道炎治疗方法,梅州早孕的检查时间,梅州妇科人工打胎手术费用价格,梅州无痛人流前做什么检查,梅州妇科盆腔炎的预防,梅州妇科病去哪家医院

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

WASHINGTON, April 4 (Xinhua) -- New research from the University of Pennsylvania School of Medicine has revealed an increased incidence of major adverse cardiac events (MACE), such as heart attack, stroke, and cardiovascular death, in patients with severe psoriasis. The study results were reported Monday at the annual American College of Cardiology meeting in New Orleans.Psoriasis is a common inflammatory skin disease, and if severe, has been demonstrated to be a risk factor for cardiovascular disease. However, the degree to which psoriasis is associated with MACE has not been defined.In a cohort study analyzing data from a general practice research database, Lead author Nehal Mehta, director of Inflammatory Risk in Penn's Preventive Cardiology program, and colleagues reviewed the case histories of over 3,600 patients with severe psoriasis and 14,300 controls. They found that patients with severe psoriasis have a 53 percent increased incidence of MACE compared to the general population. They also found that having a diagnosed case of severe psoriasis confers an additional ten-year risk of six percent on MACE.Previous work from Mehta and colleagues found that the risk of death from cardiovascular disease increased by 57 percent in patients with severe psoriasis. In addition, the relative risk of death from cardiovascular disease was even higher in younger patients, who were as young as age 40.The researchers conclude that this new estimate of increased ten-year MACE may warrant more aggressive strategies for treatment of cardiovascular risk factors in patients with psoriasis.

NEW DELHI, March 5 (Xinhua) -- Doctors in India have claimed to have successfully performed a rare robotic heart surgery on a 23- year-old person at a hospital in the southern Indian city of Chennai, local media reported Saturday.Dr. R. Ravi Kumar, the Director of the Institute of Cardiovascular Disease at the Chettinad Health City, said the robotically assisted procedure involved replacing both the mitral and the aortal valve simultaneously.The surgery carried out on D. Vijayakanth, an auto driver from Vellore, was done by a three armed robot, took four hours and cost 225,000 rupees (4,500 U.S. dollars)."The best part about using a robot in cardiac surgery is that the patient's heart need not be opened and the surgery can be done using a small 4cm incision. This is not possible with normal surgeries without a robot," Dr Ravi Kumar was quoted by local daily The Times of India as saying.Robotic surgery, which is fairly new in the country, can be used for a gamut of medical procedures, said Dr Ravi Kumar."It requires a lot of precision and intense training because though the robotic hands do the surgery, it has to be controlled by a trained surgeon. One of the biggest disadvantages is the lack of sensory perception which is there when the surgeon actually does the surgery himself," he said.

LOS ANGELES, April 10 (Xinhua) -- Drinking green tea and practicing Taichi may promote bone health of postmenopausal women and reduce the risk of inflammation, a new study suggests.The study, conducted by researchers at the Laura W. Bush Institute for Women's Health at the Texas Tech University Health Sciences Center, focused on postmenopausal women and investigated the potential for green tea to work synergistically with Taichi in enhancing bone strength of postmenopausal women.Originating as a martial art in China, Taichi is a mind-body exercise that utilizes slow, gentle movements to build strength and flexibility, as well as deep breathing and relaxation, to move qi, or vital energy, throughout the body.The study findings were published Sunday at EurekAlert.org, the website of the American Association for the Advancement of Science (AAAS).Carried out as a double-blind, placebo-controlled, intervention trial (the "holy grail" of scientific studies), this experiment involved 171 postmenopausal women with the average age of 57 who had weak bones but not full-fledged osteoporosis. Subjects were divided into 4 groups -- placebo: starch pill (placebo) and no Taichi; GTP or green tea polyphenols (500 mg/day) and no Taichi; Placebo plus Taichi (starch pill and practising Taichi three times a week); and GTP plus Taichi.The study lasted for 6 months, during which blood and urine samples were collected and muscle strength assessed.The results show that consumption of GTP (at a level equivalent to about four-six cups of steeped green tea daily) and participation in Taichi independently enhanced markers of bone health by three and six months, respectively. A similar effect was found for muscle strength at the 6-month time point. Participants taking Taichi classes also reported significant beneficial effects in quality of life in terms of improving their emotional and mental health.Perhaps most remarkable, however, was the substantial effect that both GTP and Taichi had on biological markers of oxidative stress. Because oxidative stress is a main precursor to inflammation, this finding suggests that green tea and Taichi may help reduce the underlying etiology of not only osteoporosis, but other inflammatory diseases as well.In the study, the researchers developed an animal model (the ovariectomized, middle-aged female rat), with which they could effectively study the effects of green tea consumption on protection against breakdown of the bone's microarchitecture, according to the AAAS.In humans, this can lead to osteoporosis, a condition common to older women. The researchers say what they have learned from the animal models might also be applicable to postmenopausal women.There is a "favorable effect of modest green tea consumption on bone remodeling in this pre-osteoporotic population," said lead researcher Dr. Chwan-Li (Leslie) Shen, an associate professor at the institute.The researchers plan to soon complete a more long-term study utilizing more technically savvy measures of bone density, according to the AAAS.